

USSN 10/687,540, filed October 15, 2003
Docket No. 1103326-0596
Page 2 of 5

AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-18 (canceled)

19. (New) A method for inhibiting thrombin in a mammal, comprising administering a therapeutically effective amount of an aqueous solution of a low molecular weight peptide-based thrombin inhibitor or a salt thereof to the mammal, wherein the solution is administered from a primary package sealed with a stopper or plunger comprising bromobutyl rubber.

20. (New) The method according to claim 19, wherein the primary package is selected from the group consisting of vials, bottles, cartridges, and prefilled syringes.

21. (New) The method according to claim 19, wherein the thrombin inhibitor is a gatan.

22. (New) The method according to claim 19, wherein the thrombin inhibitor is inogatan.

23. (New) The method according to claim 19, wherein the thrombin inhibitor is melagatan.

24. (New) The method according to claim 19, wherein the thrombin inhibitor is (glycine, N-[1-cyclohexyl-2-[2-[[[4-[(hydroxy-imino)-aminomethyl]-phenyl]-methyl]-amino]-carbonyl]-1-azetidyl]-2-oxoethyl]-, ethyl ester, [S-(R*,S*)]-).

25. (New) The method according to claim 19, wherein the solution is administered parenterally.

26. (New) The method according to claim 19, wherein the pH of the solution is in the range of about 3 to 8.

27. (New) The method according to claim 26, wherein the pH of the solution is about 5.

28. (New) The method according to claim 19, wherein the solution further comprises hydroxy-propyl- β -cyclodextrin.

29. (New) The method according to claim 19, wherein the solution further comprises NaCl.

- USSN 10/687,540, filed October 15, 2003
Docket No. 1103326-0596
Page 3 of 5

30. (New) The method according to claim 19, wherein the concentration of the thrombin inhibitor in the solution is in the range of 0.001-100 mg/ml.

31. (New) The method according to claim 30, wherein the concentration of the thrombin inhibitor in solution is the range of 2.5-20 mg/ml.

32. (New) The method according to claim 19, wherein the bromobutyl rubber consists of, or corresponds to, the bromobutyl rubber selected from the group consisting of PH 4023/50; W 4416/50; and FM 257.